# Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders

> **NCT05792462** · PHASE1,PHASE2 · RECRUITING · sponsor: **Tianjin Medical University General Hospital** · enrollment: 12 (estimated)

## Conditions studied

- NMO Spectrum Disorder

## Interventions

- **DRUG:** Baricitinib

## Key facts

- **NCT ID:** NCT05792462
- **Lead sponsor:** Tianjin Medical University General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-15
- **Primary completion:** 2025-12-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2024-10-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05792462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05792462, "Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05792462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*